B+
Bull case
25%
Probability
Target price
$24.00
+118.6% vs current
ANGO
AngioDynamicsBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$17.50
+59.4% vs current
B-
Bear case
20%
Probability
Target price
$8.50
-22.6% vs current
AI sentiment snapshot
Latest data as of 2026-04-03
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Tone in filings and recent releases is cautious but execution-focused; the 10-K flags acquisition/restructuring topics while the 10-Q shows typical quarterly balance-sheet movements, implying mixed near-term sentiment but material upside if cost-savings arrive [#10-K-2025-07-18][#10-Q-2026-04-02].
RankAlpha Sentiment AI - 2026-04-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystRealization of restructuring and acquisition synergiesHigh impact
Management disclosed acquisition, restructuring and other items in the 2025 Form 10-K; market-visible cost-savings and integration benefits are expected to flow through fiscal 2026 operating results, supporting margin expansion and EPS upside [#10-K-2025-07-18][#10-Q-2026-04-02].
2026-07-31eventFiscal 2026 year-end procedure volumes & margins (FY end 2026-05-31)High impact
Procedure-volume recovery and margin progression through FY2026 will be a company-specific driver; investors should watch reported volumes and gross-margin deltas in the FY2026 results window (assume end of reporting period 2026-05-31) as the next clear operating re-rating opportunity [#10-Q-2026-04-02][#10-K-2025-07-18].
2026-07-31catalystNear-term results volatility from procedure mix and working-capital swingsHigh impact
Quarterly 10-Q disclosures show balance-sheet and working-capital line-item activity that can drive short-term EPS and cash-flow revisions; this raises risk of shorter-term stock weakness around quarterly filings [#10-Q-2026-04-02].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-03 • Updated nightlySource: Internal modelMethodology